Press releases

A new Italian scientific case report, from a team at Campus Bio-Medico in Rome, detailing the Chordate treatment method Ozilia, reports on a 60-year-old...
Chordate Medical's CEO, Anders Weilandt, will present Ozilia at Swiss Nordic Bio in Zurich on March 7th. Swiss Nordic Bio is a high-level partnering...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG...
Germany is one of the markets Chordate Medical is focusing on to demonstrate proof of concept by gaining market shares with the Ozilia treatment for chronic...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG...
Chordate Medical Holding AB (publ), ("Chordate," "the Company") announces that the European Patent Office has granted Chordate's...
Chordate Medical has signed an agreement with another clinic for the Ozilia treatment for chronic migraine. The client is a specialist clinic in Munich...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG...
The following resolutions was adopted at the extraordinary general meeting of Chordate Medical Holding AB (publ) held on January 26th, 2024. Reduction...

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact